http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 27 Jul 2026 07:23:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26815982.html si-local-file:///var/storage/secattach/20260727/26815982.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26815982.html Mon, 27 Jul 2026 07:23:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26815982.html si-local-file:///var/storage/secattach/20260727/26815982.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26815982.html Mon, 27 Jul 2026 07:23:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26815982.html si-local-file:///var/storage/secattach/20260727/26815982.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26815982.html Mon, 27 Jul 2026 07:23:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Corporate+News/Evogene+and+ELEO+team+up+on+oral+PCSK9+inhibitor+discovery/26798598.html <p>Evogene Ltd. (Nasdaq: EVGN) and South Korean biotechnology company ELEO Inc. announced a scientific collaboration to discover and develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases.</p><p>Under the agreement, Evogene will apply its ChemPass AI™ computational chemistry platform to generate and optimize small-molecule candidates based on parameters including oral potency, bioavailability, selectivity, and drug-like properties. ELEO will contribute biological expertise, including target validation, PCSK9 expression suppression models, and screening platforms to experimentally validate the computationally designed candidates.</p><p>The global PCSK9 inhibitor market is projected to grow from approximately $4.4 billion in 2025 to more http://www.streetinsider.com/Corporate+News/Evogene+and+ELEO+team+up+on+oral+PCSK9+inhibitor+discovery/26798598.html Wed, 22 Jul 2026 08:02:39 -0400 EVGN http://www.streetinsider.com/Press+Releases/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html <div class="xn-content"> <p class="prntac"><i>Collaboration combines <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene's</span> AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity</i></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location> and DAEJEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, and <span>ELEO Inc.</span>, a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, today announced a strategic scientific http://www.streetinsider.com/Press+Releases/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html Wed, 22 Jul 2026 08:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Press+Releases/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html <div class="xn-content"> <p class="prntac"><i>Collaboration combines <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene's</span> AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity</i></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location> and DAEJEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, and <span>ELEO Inc.</span>, a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, today announced a strategic scientific http://www.streetinsider.com/Press+Releases/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html Wed, 22 Jul 2026 08:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Press+Releases/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html <div class="xn-content"> <p class="prntac"><i>Collaboration combines <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene's</span> AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity</i></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location> and DAEJEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, and <span>ELEO Inc.</span>, a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, today announced a strategic scientific http://www.streetinsider.com/Press+Releases/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html Wed, 22 Jul 2026 08:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/PRNewswire/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html <div class="xn-content"> <p class="prntac"><i>Collaboration combines <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene's</span> AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity</i></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location> and DAEJEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, and <span>ELEO Inc.</span>, a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, today announced a strategic scientific http://www.streetinsider.com/PRNewswire/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html Wed, 22 Jul 2026 08:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/PRNewswire/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html <div class="xn-content"> <p class="prntac"><i>Collaboration combines <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene's</span> AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity</i></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location> and DAEJEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, and <span>ELEO Inc.</span>, a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, today announced a strategic scientific http://www.streetinsider.com/PRNewswire/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html Wed, 22 Jul 2026 08:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/PRNewswire/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html <div class="xn-content"> <p class="prntac"><i>Collaboration combines <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene's</span> AI-driven computational chemistry platform with ELEO's proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity</i></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location> and DAEJEON, <location value="LC/kr" idsrc="xmltag.org" >South Korea</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, and <span>ELEO Inc.</span>, a South Korean biotechnology company focused on developing innovative therapies for chronic and difficult-to-treat diseases, today announced a strategic scientific http://www.streetinsider.com/PRNewswire/Evogene+Ltd.+and+ELEO+Inc.+Announce+Collaboration+to+Develop+Next-Generation+Oral+Small-Molecule+PCSK9+Pathway+Inhibitors+for+Hyperlipidemia+and+Cardiovascular+Diseases/26798484.html Wed, 22 Jul 2026 08:00:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26789552.html si-local-file:///var/storage/secattach/20260720/26789552.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26789552.html Mon, 20 Jul 2026 15:47:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26789552.html si-local-file:///var/storage/secattach/20260720/26789552.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26789552.html Mon, 20 Jul 2026 15:47:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26789552.html si-local-file:///var/storage/secattach/20260720/26789552.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++Evogene+Ltd.+++++++++++++++++++++++++++Filed+by%3A+L.I.A.+Pure+Capital+Ltd/26789552.html Mon, 20 Jul 2026 15:47:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26784360.html si-local-file:///var/storage/secattach/20260717/26784360.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26784360.html Fri, 17 Jul 2026 16:06:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26784360.html si-local-file:///var/storage/secattach/20260717/26784360.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26784360.html Fri, 17 Jul 2026 16:06:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26784360.html si-local-file:///var/storage/secattach/20260717/26784360.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Evogene+Ltd.+++++++++++++++++++++++++/26784360.html Fri, 17 Jul 2026 16:06:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jul+17/26784301.html si-local-file:///var/storage/secattach/20260717/26784301.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jul+17/26784301.html Fri, 17 Jul 2026 16:03:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jul+17/26784301.html si-local-file:///var/storage/secattach/20260717/26784301.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jul+17/26784301.html Fri, 17 Jul 2026 16:03:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jul+17/26784301.html si-local-file:///var/storage/secattach/20260717/26784301.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Evogene+Ltd.++++++++++++++For%3A+Jul+17/26784301.html Fri, 17 Jul 2026 16:03:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Corporate+News/AgPlenus+launches+AI+model+to+predict+antifungal+potency/26770898.html <p>AgPlenus Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced the launch of its Antifungal Potency Predictor (APP), a machine learning model designed to forecast the antifungal potency of small molecules based on their chemical structures, before chemical synthesis or biological testing takes place.</p><p>The model has been integrated into Evogene's ChemPass AI for Ag™ platform and was trained on AgPlenus' proprietary datasets. According to the company, the APP is intended to reduce the number of molecules requiring experimental evaluation by identifying candidates with higher probabilities of success at early discovery stages.</p><p>AgPlenus said the model is expected to support its internal http://www.streetinsider.com/Corporate+News/AgPlenus+launches+AI+model+to+predict+antifungal+potency/26770898.html Wed, 15 Jul 2026 07:31:10 -0400 EVGN http://www.streetinsider.com/Press+Releases/AgPlenus+Launches+Novel+AI+Model+for+Predicting+Antifungal+Potency%2C+Expanding+ChemPass+AI+for+Ag%E2%84%A2+Capabilities/26770880.html <div class="xn-content"> <p class="prntac"><b><i>New AI model enables ChemPass AI for Ag™ to identify and prioritize antifungal molecules with a higher probability of biological success</i></b><b><i> at early discovery stages</i></b></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <b><span>AgPlenus Ltd.</span></b>, a company developing novel, sustainable crop protection products and a subsidiary of <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> (NASDAQ: EVGN) (TASE: EVGN), today announced the launch of its Antifungal Potency Predictor (APP). This new machine learning model predicts the antifungal potency of small molecules directly from their chemical structures, expanding the capabilities of <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene's</span> <i>ChemPass AI for Ag™ </i>platform by forecasting biological efficacy http://www.streetinsider.com/Press+Releases/AgPlenus+Launches+Novel+AI+Model+for+Predicting+Antifungal+Potency%2C+Expanding+ChemPass+AI+for+Ag%E2%84%A2+Capabilities/26770880.html Wed, 15 Jul 2026 07:30:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Press+Releases/AgPlenus+Launches+Novel+AI+Model+for+Predicting+Antifungal+Potency%2C+Expanding+ChemPass+AI+for+Ag%E2%84%A2+Capabilities/26770880.html <div class="xn-content"> <p class="prntac"><b><i>New AI model enables ChemPass AI for Ag™ to identify and prioritize antifungal molecules with a higher probability of biological success</i></b><b><i> at early discovery stages</i></b></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <b><span>AgPlenus Ltd.</span></b>, a company developing novel, sustainable crop protection products and a subsidiary of <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> (NASDAQ: EVGN) (TASE: EVGN), today announced the launch of its Antifungal Potency Predictor (APP). This new machine learning model predicts the antifungal potency of small molecules directly from their chemical structures, expanding the capabilities of <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene's</span> <i>ChemPass AI for Ag™ </i>platform by forecasting biological efficacy http://www.streetinsider.com/Press+Releases/AgPlenus+Launches+Novel+AI+Model+for+Predicting+Antifungal+Potency%2C+Expanding+ChemPass+AI+for+Ag%E2%84%A2+Capabilities/26770880.html Wed, 15 Jul 2026 07:30:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/Press+Releases/AgPlenus+Launches+Novel+AI+Model+for+Predicting+Antifungal+Potency%2C+Expanding+ChemPass+AI+for+Ag%E2%84%A2+Capabilities/26770880.html <div class="xn-content"> <p class="prntac"><b><i>New AI model enables ChemPass AI for Ag™ to identify and prioritize antifungal molecules with a higher probability of biological success</i></b><b><i> at early discovery stages</i></b></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <b><span>AgPlenus Ltd.</span></b>, a company developing novel, sustainable crop protection products and a subsidiary of <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> (NASDAQ: EVGN) (TASE: EVGN), today announced the launch of its Antifungal Potency Predictor (APP). This new machine learning model predicts the antifungal potency of small molecules directly from their chemical structures, expanding the capabilities of <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene's</span> <i>ChemPass AI for Ag™ </i>platform by forecasting biological efficacy http://www.streetinsider.com/Press+Releases/AgPlenus+Launches+Novel+AI+Model+for+Predicting+Antifungal+Potency%2C+Expanding+ChemPass+AI+for+Ag%E2%84%A2+Capabilities/26770880.html Wed, 15 Jul 2026 07:30:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/PRNewswire/AgPlenus+Launches+Novel+AI+Model+for+Predicting+Antifungal+Potency%2C+Expanding+ChemPass+AI+for+Ag%E2%84%A2+Capabilities/26770880.html <div class="xn-content"> <p class="prntac"><b><i>New AI model enables ChemPass AI for Ag™ to identify and prioritize antifungal molecules with a higher probability of biological success</i></b><b><i> at early discovery stages</i></b></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <b><span>AgPlenus Ltd.</span></b>, a company developing novel, sustainable crop protection products and a subsidiary of <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> (NASDAQ: EVGN) (TASE: EVGN), today announced the launch of its Antifungal Potency Predictor (APP). This new machine learning model predicts the antifungal potency of small molecules directly from their chemical structures, expanding the capabilities of <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene's</span> <i>ChemPass AI for Ag™ </i>platform by forecasting biological efficacy http://www.streetinsider.com/PRNewswire/AgPlenus+Launches+Novel+AI+Model+for+Predicting+Antifungal+Potency%2C+Expanding+ChemPass+AI+for+Ag%E2%84%A2+Capabilities/26770880.html Wed, 15 Jul 2026 07:30:00 -0400 EVGN EVGN O.05114039 http://www.streetinsider.com/PRNewswire/AgPlenus+Launches+Novel+AI+Model+for+Predicting+Antifungal+Potency%2C+Expanding+ChemPass+AI+for+Ag%E2%84%A2+Capabilities/26770880.html <div class="xn-content"> <p class="prntac"><b><i>New AI model enables ChemPass AI for Ag™ to identify and prioritize antifungal molecules with a higher probability of biological success</i></b><b><i> at early discovery stages</i></b></p><p><span class="legendSpanClass"><location value="LU/il..rehovot" idsrc="xmltag.org" >REHOVOT, Israel</location></span>, <span class="legendSpanClass"><chron>July 15, 2026</chron></span> /PRNewswire/ -- <b><span>AgPlenus Ltd.</span></b>, a company developing novel, sustainable crop protection products and a subsidiary of <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene Ltd.</span> (NASDAQ: EVGN) (TASE: EVGN), today announced the launch of its Antifungal Potency Predictor (APP). This new machine learning model predicts the antifungal potency of small molecules directly from their chemical structures, expanding the capabilities of <span value="NASDAQ-NMS:EVGN" idsrc="xmltag.org" >Evogene's</span> <i>ChemPass AI for Ag™ </i>platform by forecasting biological efficacy http://www.streetinsider.com/PRNewswire/AgPlenus+Launches+Novel+AI+Model+for+Predicting+Antifungal+Potency%2C+Expanding+ChemPass+AI+for+Ag%E2%84%A2+Capabilities/26770880.html Wed, 15 Jul 2026 07:30:00 -0400 EVGN EVGN O.05114039